 |
 |
 |
 |
 |
 |
 |
FDA Approves Xiaflex for Debilitating Hand Condition
We are excited to announce that the Food and Drug Administration recently approved a drug called Xiaflex, which can treat a progressive hand disease known as Dupuytren's contracture. Typically found in Caucasians and men over 50 years old, this condition affects a person’s ability to straighten and properly use their fingers.
Orthopaedic Specialty Clinic has been selected as a designated site for the recently approved Xiaflex. As such, Orthopaedic Specialty Clinic is one of only a few sites that is certified to make Xiaflex available to patients. This new treatment will give patients another option for a condition that traditionally has required surgery
Xiaflex is injected directly into the collagen cord of the patient’s hand in a series of three shots by the medical professional. Over a 24-48 hour period, the active ingredients in the drug work by breaking down the excessive buildup of collagen in the hand, the primary cause of the condition.
In a 66-patient study cited by the FDA, 44 percent of those injected with Xiaflex were treated successfully, compared to 5 percent for patients who received a placebo.
According to the FDA:
-
Dupuytren's contracture affects the connective tissue found beneath the skin in the palm of the hand. Too much collagen can build up, forming
thick, rope-like cords of tissue that can prevent the fingers from being able to relax and straighten normally.
Xiaflex is a biologic drug made from the protein product of a living organism. It works by breaking down the excessive buildup of collagen in the hand.